Malignant neoplasm of bone and articular cartilage

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

Primary bone cancer is curable in a defined subset, not in most cases. Localized, resectable osteosarcoma and Ewing sarcoma can often be cured when surgery is combined with multi-agent chemotherapy; five-year survival is around 70–80%. Metastatic disease remains largely incurable, and high-grade chondrosarcoma often resists chemotherapy. Survival for localized tumors has improved steadily since the 1970s, while advanced disease has improved far less. The most important milestone remains the introduction of multi-agent chemotherapy alongside planned sarcoma surgery. That combination changed localized bone cancer from almost always fatal to often curable. Research is active: 76 trials are currently underway, 64 of them started in the last five years, and one has reached phase 3.

How curable is bone cancer today?

It is curable in a defined subset: localized osteosarcoma and Ewing sarcoma often are cured with surgery plus chemotherapy, giving five-year survival around 70–80 percent. Once the cancer has spread, cure is rare. High-grade chondrosarcoma often does not respond to chemotherapy.

Has survival improved over recent decades?

Yes, mainly for localized disease. Since multi-agent chemotherapy was added to surgery, survival has risen sharply from the low rates seen in the 1970s. The same improvements have not yet fully extended to metastatic or chemoresistant disease.

Why is metastatic bone cancer so hard to cure?

When the cancer has spread, surgery cannot remove every deposit, and chemotherapy is not strong enough to eliminate all of them. Some subtypes, especially high-grade chondrosarcoma, have little sensitivity to available drugs, leaving systemic disease very difficult to cure.

What has been the biggest research milestone?

The biggest milestone is the shift from amputation alone to limb-salvage surgery combined with multi-agent chemotherapy. This approach, developed over the past few decades, turned localized bone sarcoma from usually fatal into curable for a meaningful subset.

What are current trials investigating?

There are 76 active trials; 64 began in the last five years, and only one is phase 3. These early-phase trials are exploring immunotherapies, new drug combinations, and better ways to shrink tumors before surgery. No universal breakthrough should be expected immediately.